Entecavir Mylan

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

entekavir monohidrat

Available from:

Mylan Pharmaceuticals Limited

ATC code:

J05AF10

INN (International Name):

entecavir

Therapeutic group:

Antivirusi za sistemsko uporabo

Therapeutic area:

Hepatitis B

Therapeutic indications:

Entecavir Mylan is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. decompensated bolezen jeter. Za obe nadomestilo in decompensated bolezni jeter, ta navedba temelji na kliničnem preskušanju podatkov v nucleoside naivnih bolnikov z HBeAg pozitivnih in HBeAg negativnih HBV okužbe. Glede bolnikov z lamivudinom neodzivnega hepatitisa B. Entecavir Mylan je prav tako primerna za zdravljenje kronične HBV okužbe v nucleoside naivno pediatričnih bolnikih od 2 do.

Product summary:

Revision: 6

Authorization status:

Pooblaščeni

Authorization date:

2017-09-18

Patient Information leaflet

                                29
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Mylan Pharmaceuticals Limited
Damastown Industrial Park,
Mulhuddart, Dublin 15,
DUBLIN
Irska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/17/1227/003
EU/1/17/1227/003
EU/1/17/1227/005
13.
ŠTEVILKA SERIJE
_ _
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Entekavir Viatris 0,5 mg filmsko obložene tablete
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
30
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT
1.
IME ZDRAVILA
_ _
Entekavir Viatris 0,5 mg filmsko obložene tablete
entekavir
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Mylan Pharmaceuticals Limited
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
31
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT ZA POSAMEZNI ODMEREK
1.
IME ZDRAVILA
_ _
Entekavir Viatris 0,5 mg filmsko obložene tablete
entekavir
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Mylan Pharmaceuticals Limited
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
32
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA ZA PLASTENKO
1.
IME ZDRAVILA
Entekavir Viatris 0,5 mg filmsko obložene tablete
entekavir
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena filmsko obložena tableta vsebuje 0,5 mg entekavirja v obliki
entekavir monohidrata,
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje tudi laktozo. Za dodatne informacije glejte navodilo za
uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
filmsko obložena tableta
30 filmsko obloženih tablet
90 filmsko obloženih tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo navodilo.
peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA I
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Entekavir Viatris 0,5 mg filmsko obložene tablete
Entekavir Viatris 1 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Entekavir Viatris 0,5 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 0,5 mg entekavirja v obliki
entekavir monohidrata.
Entekavir Viatris 1 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 1 mg entekavirja v obliki
entekavir monohidrata.
Pomožna snov z znanim učinkom
_Entekavir Viatris_
_0,5 mg filmsko obložene tablete_
Ena filmsko obložena tableta vsebuje 62,5 mg laktoze monohidrata.
_Entekavir Viatris_
_1 mg filmsko obložene tablete_
Ena filmsko obložena tableta vsebuje 125 mg laktoze monohidrata.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta
Entekavir Viatris 0,5 mg filmsko obložene tablete
Bela, filmsko obložena, okrogla, bikonveksna tableta z zaobljenim
robom in z vtisnjeno oznako »M«
na eni strani in »EA« na drugi strani. Premer: približno 6,8 mm.
Entekavir Viatris 1 mg filmsko obložene tablete
Bela, filmsko obložena, okrogla, bikonveksna tableta z zaobljenim
robom in z vtisnjeno oznako »M«
na eni strani in »EB« na drugi strani. Premer: približno 8,8 mm.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Entekavir Viatris je indicirano za zdravljenje kronične
okužbe z virusom hepatitisa B (HBV)
(glejte poglavje 5.1) pri odraslih:

s kompenzirano boleznijo jeter in dokazano aktivno replikacijo virusa,
persistentno
povečanimi vrednostmi serumske alanin-aminotransferaze (ALT) in
histološko dokazanim
aktivnim vnetjem in/ali fibrozo.

z dekompenzirano boleznijo jeter (glejte poglavje 4.4).
Pri obeh, kompenzirani in dekompenzirani bolezni jeter, indikacija
temelji na podatkih kliničnega
preskušanja pri HBeAg pozitivnih in HBeAg negativnih bolnikih,
okuženih s HBV, ki se še niso
zdravili z nukleozidi. Glede bolnikov s hepatitisom B, neodzivnim na
lamivudin, glejte poglavja 4.2,

                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-01-2024
Public Assessment Report Public Assessment Report Bulgarian 26-10-2017
Patient Information leaflet Patient Information leaflet Spanish 16-01-2024
Public Assessment Report Public Assessment Report Spanish 26-10-2017
Patient Information leaflet Patient Information leaflet Czech 16-01-2024
Public Assessment Report Public Assessment Report Czech 26-10-2017
Patient Information leaflet Patient Information leaflet Danish 16-01-2024
Public Assessment Report Public Assessment Report Danish 26-10-2017
Patient Information leaflet Patient Information leaflet German 16-01-2024
Public Assessment Report Public Assessment Report German 26-10-2017
Patient Information leaflet Patient Information leaflet Estonian 16-01-2024
Public Assessment Report Public Assessment Report Estonian 26-10-2017
Patient Information leaflet Patient Information leaflet Greek 16-01-2024
Public Assessment Report Public Assessment Report Greek 26-10-2017
Patient Information leaflet Patient Information leaflet English 16-01-2024
Public Assessment Report Public Assessment Report English 26-10-2017
Patient Information leaflet Patient Information leaflet French 16-01-2024
Public Assessment Report Public Assessment Report French 26-10-2017
Patient Information leaflet Patient Information leaflet Italian 16-01-2024
Public Assessment Report Public Assessment Report Italian 26-10-2017
Patient Information leaflet Patient Information leaflet Latvian 16-01-2024
Public Assessment Report Public Assessment Report Latvian 26-10-2017
Patient Information leaflet Patient Information leaflet Lithuanian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-01-2024
Public Assessment Report Public Assessment Report Lithuanian 26-10-2017
Patient Information leaflet Patient Information leaflet Hungarian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 16-01-2024
Public Assessment Report Public Assessment Report Hungarian 26-10-2017
Patient Information leaflet Patient Information leaflet Maltese 16-01-2024
Public Assessment Report Public Assessment Report Maltese 26-10-2017
Patient Information leaflet Patient Information leaflet Dutch 16-01-2024
Public Assessment Report Public Assessment Report Dutch 26-10-2017
Patient Information leaflet Patient Information leaflet Polish 16-01-2024
Public Assessment Report Public Assessment Report Polish 26-10-2017
Patient Information leaflet Patient Information leaflet Portuguese 16-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 16-01-2024
Public Assessment Report Public Assessment Report Portuguese 26-10-2017
Patient Information leaflet Patient Information leaflet Romanian 16-01-2024
Public Assessment Report Public Assessment Report Romanian 26-10-2017
Patient Information leaflet Patient Information leaflet Slovak 16-01-2024
Public Assessment Report Public Assessment Report Slovak 26-10-2017
Patient Information leaflet Patient Information leaflet Finnish 16-01-2024
Public Assessment Report Public Assessment Report Finnish 26-10-2017
Patient Information leaflet Patient Information leaflet Swedish 16-01-2024
Public Assessment Report Public Assessment Report Swedish 26-10-2017
Patient Information leaflet Patient Information leaflet Norwegian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 16-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 16-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 16-01-2024
Patient Information leaflet Patient Information leaflet Croatian 16-01-2024
Public Assessment Report Public Assessment Report Croatian 26-10-2017

Search alerts related to this product